CervoMed reports 12-week NfL decline in nfvPPA trial

what happened

TradingView, citing CervoMed Inc.’s original press release distributed by GlobeNewswire, reported that mean plasma NfL declined during the first 12 weeks of the open-label phase of the company’s Phase 2a nfvPPA trial. The study enrolled 25 patients, and no new safety signals were reported.

The biomarker decrease contrasts with increases expected in the natural history of the disease and was greater among patients whose baseline NfL was at or above the median. Twenty-four-week biomarker results are expected in November 2026, while topline clinical data are scheduled for the first quarter of 2027.

The study is early-stage and open-label, limiting the conclusions that can be drawn from the signal. The next key questions are whether the NfL decline persists and whether it translates into clinical benefit during the randomized withdrawal phase.

why it matters

The November 2026 biomarker update is the nearest stated catalyst, but its interpretation will remain constrained by the small, open-label study. Clinical data in Q1 2027 are expected to clarify whether the biomarker change corresponds to patient benefit. The result is an early signal in a rare FTD subtype and adds to CervoMed’s earlier DLB development work.

instruments